In last trading session, ProKidney Corp (NASDAQ:PROK) saw 7.4 million shares changing hands with its beta currently measuring 1.41. Company’s recent per share price level of $3.52 trading at -$0.21 or -5.63% at ring of the bell on the day assigns it a market valuation of $1.03B. That closing price of PROK’s stock is at a discount of -102.56% from its 52-week high price of $7.13 and is indicating a premium of 86.93% from its 52-week low price of $0.46. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 67.48 million shares which gives us an average trading volume of 12.68 million if we extend that period to 3-months.
For ProKidney Corp (PROK), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.29. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
ProKidney Corp (NASDAQ:PROK) trade information
ProKidney Corp’s shares saw a change of 47.28% in year-to-date performance and have moved -32.05% in past 5-day. ProKidney Corp (NASDAQ:PROK) showed a performance of 256.89% in past 30-days. Number of shares sold short was 16.8 million shares which calculate 32.47 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 29.6% to its current value. Analysts have been projecting 3 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would jump 14.77% in reaching the projected high whereas dropping to the targeted low would mean a gain of 14.77% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around 10.31% while estimates for its earnings growth in next 5 years are of -4.46%.
ProKidney Corp (NASDAQ:PROK)’s Major holders
Insiders are in possession of 30.05% of company’s total shares while institution are holding 41.66 percent of that, with stock having share float percentage of 59.55%. Investors also watch the number of corporate investors in a company very closely, which is 41.66% institutions for ProKidney Corp that are currently holding shares of the company. MORGAN STANLEY is the top institutional holder at PROK for having 14.45 million shares of worth $35.54 million. And as of 2024-06-30, it was holding 19.034 of the company’s outstanding shares.
The second largest institutional holder is SUVRETTA CAPITAL MANAGEMENT, LLC, which was holding about 9.34 million shares on 2024-06-30. The number of shares represents firm’s hold over 12.306 of outstanding shares, having a total worth of $22.98 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 2.97 shares of worth $10.45 million or 2.29% of the total outstanding shares. The later fund manager was in possession of 2.58 shares on May 31, 2025 , making its stake of worth around $9.08 million in the company or a holder of 1.99% of company’s stock.
